TriangleNCT00387426 · STUDY IN CONTEXT
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
Draft scope assessment: unclear. Attached because the study's own record describes refractory disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-myeloid-leukemia-mylotarg-85925ef2
- nct id
- NCT00387426
- trial label
- Sunitinib in Treating Patients With Idiopathic Myelofibrosis
- applicability
- unclear
- applicability note
- Attached because the study's own record describes refractory disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 1
- harms Count
- 1
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-myeloid-leukemia-mylotarg-85925ef2
- nct id
- NCT00387426
- outcome key
- om-0000
- source section id
- NCT00387426-om-0000
- source outcome index
- 0
- endpoint
- Number of Participants With Objective Clinical Response to Sunitinib Therapy
- endpoint definition
- Participant response assessed after two cycles of therapy according to categories: 1) complete response, 2) partial response, 3) clinical improvement, 4) stable disease 5) progressive disease, 6) early death from malignant disease, 7) early death from toxicity, 8) early death because of other cause, or 9) unknown (not assessable, insufficient data).
- time origin
- After two 6-week treatment courses (12 weeks)
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- All participants assessed for response.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-myeloid-leukemia-mylotarg-85925ef2
- nct id
- NCT00387426
- outcome key
- om-0000
- arm key
- OG000
- arm label
- Sunitinib
- regimen
- 37.5 mg orally daily for 6-week cycle
- analyzed count
- 14
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00387426-om-0000#groups/OG000
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-myeloid-leukemia-mylotarg-85925ef2
- nct id
- NCT00387426
- harm key
- EG000
- source section id
- NCT00387426-ae
- event group key
- EG000
- event group label
- Sunitinib
- serious affected
- 7
- serious at risk
- 14
- other affected
- 14
- other at risk
- 14
- frequency threshold
- 5
- collection period
- 2 years
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice